Back to Search
Start Over
Treatment and relapse in breast cancer show significant correlations to noninvasive testing using urinary and plasma DNA.
- Source :
- Future Oncology; May2020, Vol. 16 Issue 13, p849-858, 10p
- Publication Year :
- 2020
-
Abstract
- Aim: Circulating tumor DNA is promising for routine monitoring of breast cancer. Noninvasive testing allows regular probing using plasma and urine samples. Methods: Peripheral blood and simultaneous urine collection from patients were quantified. Concordance between methods were made. Serial time-point measurements were correlated to disease outcome. Results: Index measurements demonstrate over 90% concordance with biopsy. Receiver operating characteristics curves showed over 0.95 for both plasma and urine results comparing with controls. Patients with lower risk of relapse experienced greater declines in detected DNA levels. Maximal declines were registered at 4.0- and 6.8-fold for plasma and urine results, respectively. Conclusion: Measuring and monitoring DNA levels complement existing testing regimes and provides better risk profiling of patients for possible relapse. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14796694
- Volume :
- 16
- Issue :
- 13
- Database :
- Complementary Index
- Journal :
- Future Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 142846067
- Full Text :
- https://doi.org/10.2217/fon-2020-0074